Testing a genetic tool to predict heart complications during stent placement

This trial is testing a precision medicine tool called the ABCD-GENE score that combines your genetic makeup and medical history to predict whether you're at higher risk of heart damage during a planned stent placement (a common procedure to open blocked heart arteries). The score looks at five factors: your age, body weight, kidney function, whether you have diabetes, and a specific genetic variation that affects how your body processes the blood thinner clopidogrel. By identifying patients at higher risk, doctors may be able to adjust your blood-thinning medication to better protect your heart.

During stent placement, some patients experience heart damage or blood clots, which can happen in up to 30% of cases and lead to serious complications. About one-third of patients don't respond well to the standard blood thinner clopidogrel because of genetic differences. This study aims to validate whether the ABCD-GENE score can reliably identify those at-risk patients before the procedure, so treatment can be adjusted to improve outcomes.